Literature DB >> 9226188

Cytokine-facilitated transduction leads to low-level engraftment in nonablated hosts.

E L Kittler1, S O Peters, R B Crittenden, M E Debatis, H S Ramshaw, F M Stewart, P J Quesenberry.   

Abstract

Using a murine bone marrow transplantation model, we evaluated the long-term engraftment of retrovirally transduced bone marrow cells in nonmyeloablated hosts. Male bone marrow was stimulated in a cocktail of interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor (SCF) for 48 hours, then cocultured on the retroviral producer line MDR18.1 for an additional 24 hours. Functional transduction of hematopoietic progenitors was detected in vitro by reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of multiple drug resistance 1 (MDR1) mRNA from high proliferative potential-colony forming cell (HPP-CFC) colonies. After retroviral transduction, male bone marrow cells were injected into nonablated female mice. Transplant recipients received three TAXOL (Bristol-Myers, Princeton, NJ) injections (10 mg/kg) over a 14-month period. Transplant recipient tissues were analyzed by Southern blot and fluorescence in situ hybridization for Y-chromosome-specific sequences and showed donor cell engraftment of approximately 9%. However, polymerase chain reaction amplification of DNAs from bone marrow, spleen, and peripheral blood showed no evidence of the transduced MDR1 gene. RT-PCR analysis of total bone marrow RNA showed that transcripts from the MDR1 gene were present in a fraction of the engrafted donor cells. These data show functional transfer of the MDR1 gene into nonmyeloablated murine hosts. However, the high rates of in vitro transduction into HPP-CFC, coupled with the low in vivo engraftment rate of donor cells containing the MDR1 gene, suggest that the majority of stem cells that incorporated the retroviral construct did not stably engraft in the host. Based on additional studies that indicate that ex vivo culture of bone marrow induces an engraftment defect concomitantly with progression of cells through S phase, we propose that the cell cycle transit required for proviral integration reduces or impairs the ability of transduced cells to stably engraft.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226188

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles.

Authors:  Lee S O'Neill; Amy M Skinner; Josha A Woodward; Peter Kurre
Journal:  J Gene Med       Date:  2010-05       Impact factor: 4.565

Review 2.  The stem cell continuum: considerations on the heterogeneity and plasticity of marrow stem cells.

Authors:  Peter J Quesenberry; G Dooner; M Dooner; G Colvin
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells.

Authors:  Sarah-Katharina Kays; Kerstin B Kaufmann; Tobias Abel; Christian Brendel; Halvard Bonig; Manuel Grez; Christian J Buchholz; Sabrina Kneissl
Journal:  Stem Cells Dev       Date:  2015-01-20       Impact factor: 3.272

4.  CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells.

Authors:  Christian Brendel; Benjamin Goebel; Abriss Daniela; Martijn Brugman; Sabrina Kneissl; Joachim Schwäble; Kerstin B Kaufmann; Uta Müller-Kuller; Hana Kunkel; Linping Chen-Wichmann; Tobias Abel; Hubert Serve; Leonid Bystrykh; Christian J Buchholz; Manuel Grez
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

5.  Influence of timing of administration of 5-fluorouracil to donors on bone marrow engraftment in nonmyeloablated hosts.

Authors:  L D'Hondt; J Carlson; B Benoit; J Reilly; C Grimaldi; J Wuu; J F Lambert; M S Dooner; P J Quesenberry
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

6.  Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation.

Authors:  Katrin Hacke; Rustom Falahati; Linda Flebbe-Rehwaldt; Noriyuki Kasahara; Karin M L Gaensler
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

7.  In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector.

Authors:  Shanbao Cai; Aaron Ernstberger; Haiyan Wang; Barbara J Bailey; Jennifer R Hartwell; Anthony L Sinn; Olaf Eckermann; Yvonne Linka; W Scott Goebel; Helmut Hanenberg; Karen E Pollok
Journal:  Exp Hematol       Date:  2008-03       Impact factor: 3.084

8.  CXCR4 induction in hematopoietic progenitor cells from Fanca(-/-), -c(-/-), and -d2(-/-) mice.

Authors:  Amy M Skinner; S Lee O'Neill; Markus Grompe; Peter Kurre
Journal:  Exp Hematol       Date:  2008-03       Impact factor: 3.084

9.  ADAR1 is required for hematopoietic progenitor cell survival via RNA editing.

Authors:  Richard XuFeng; Matthew J Boyer; Hongmei Shen; Yanxin Li; Hui Yu; Yindai Gao; Qiong Yang; Qingde Wang; Tao Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-02       Impact factor: 11.205

10.  A novel competitive repopulation strategy to quantitate engraftment of ex vivo manipulated murine marrow cells in submyeloablated hosts.

Authors:  Brandon K Wyss; Justin L Meyers; Anthony L Sinn; Shanbao Cai; Karen E Pollok; W Scott Goebel
Journal:  Exp Hematol       Date:  2008-02-04       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.